Skip to main content
Journal cover image

NASH in HIV.

Publication ,  Journal Article
Cervo, A; Shengir, M; Patel, K; Sebastiani, G
Published in: Curr HIV/AIDS Rep
December 2020

PURPOSE OF REVIEW: Aging-related comorbidities, including liver disease, represent the main drivers of morbidity and mortality in people with HIV (PWH). Nonalcoholic fatty liver disease (NAFLD) seems a frequent comorbidity in aging PWH nowadays. NAFLD results from a fat deposition into the liver parenchyma that may evolve to nonalcoholic steatohepatitis (NASH), a state of hepatocellular inflammation and injury in response to the accumulated fat leading to liver fibrosis and cirrhosis. We here review the current status of knowledge regarding this emerging comorbidity in PWH. RECENT FINDINGS: Recent studies suggest that PWH are at higher risk for both NASH and NASH-related liver fibrosis. Several hypothesized pathogenic mechanisms may account for this finding, including increased metabolic comorbidities, hepatotoxic effect of lifelong antiretroviral therapy, and chronic HIV infection. In clinical practice, non-invasive diagnostic tests, such as serum biomarkers and elastography, may help identify patients with NASH-related fibrosis, thus improving risk stratification, and enhancing clinical management decisions, including early initiation of interventions such as lifestyle changes and potential pharmacologic interventions. Clinicians should remain informed of the frequency, significance, and diagnostic and management approach to NASH in PWH.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr HIV/AIDS Rep

DOI

EISSN

1548-3576

Publication Date

December 2020

Volume

17

Issue

6

Start / End Page

601 / 614

Location

United States

Related Subject Headings

  • Virology
  • Non-alcoholic Fatty Liver Disease
  • Liver Neoplasms
  • Liver Cirrhosis
  • Inflammation
  • Humans
  • HIV Infections
  • Comorbidity
  • Biomarkers
  • Anti-Retroviral Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cervo, A., Shengir, M., Patel, K., & Sebastiani, G. (2020). NASH in HIV. Curr HIV/AIDS Rep, 17(6), 601–614. https://doi.org/10.1007/s11904-020-00531-0
Cervo, Adriana, Mohamed Shengir, Keyur Patel, and Giada Sebastiani. “NASH in HIV.Curr HIV/AIDS Rep 17, no. 6 (December 2020): 601–14. https://doi.org/10.1007/s11904-020-00531-0.
Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep. 2020 Dec;17(6):601–14.
Cervo, Adriana, et al. “NASH in HIV.Curr HIV/AIDS Rep, vol. 17, no. 6, Dec. 2020, pp. 601–14. Pubmed, doi:10.1007/s11904-020-00531-0.
Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep. 2020 Dec;17(6):601–614.
Journal cover image

Published In

Curr HIV/AIDS Rep

DOI

EISSN

1548-3576

Publication Date

December 2020

Volume

17

Issue

6

Start / End Page

601 / 614

Location

United States

Related Subject Headings

  • Virology
  • Non-alcoholic Fatty Liver Disease
  • Liver Neoplasms
  • Liver Cirrhosis
  • Inflammation
  • Humans
  • HIV Infections
  • Comorbidity
  • Biomarkers
  • Anti-Retroviral Agents